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Introduction: Retinitis pigmentosa (RP) is a severe neurodegenerative disease of the retina that can lead to
blindness. Even without treatment, a clinical study with the use of stem cells is currently underway and the results
are being evaluated. In the present report we assess the vision-related quality of life in patients with RP submitted
to intravitreal use of bone marrow-derived stem cells.
Method: The study included 20 patients with RP submitted to intravitreal use of bone marrow-derived stem cells.
We evaluate the vision-related quality of life (VRQOL) of patients using the National Eye Institute Visual Function
Questionnaire-25 (NEI VFQ-25). Patients were scheduled to answer the questionnaire before treatment and 3 and
12 months after treatment.
Results: All patients completed the survey as scheduled.
There was a statistically significant improvement (P <0.05) in the quality of life of patients 3 months after treatment,
whereas by the 12th month there was no statistically significant difference from baseline.
Conclusions: Cell therapy with intravitreal use of bone marrow-derived stem cells can improve the quality of life of
patients with RP, although the improvement is lost with time. A larger number of cases will be necessary to evaluate
the repercussions of this therapy on the quality of life of these patients.
Trial registration: Clinicaltrials.gov: NCT01560715. Registered March 19, 2012.Introduction
Retinitis pigmentosa (RP) is a severe neurodegenerative
disease of the retina initially characterised by night
blindness, with progression to tunnel vision and eventual
loss of central vision and total blindness. Targeted ther-
apies for RP are complicated by the identification of
more than 40 genes linked to the dominant and reces-
sive forms of this disease [1,2].
A few new approaches to RP treatment have been re-
cently investigated, including nutritional supplementa-
tion, light reduction and gene therapy; valproic acid and
vitamin A supplementation which is the most promising,* Correspondence: rubenssiqueira@terra.com.br
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atic. Therefore, there is currently no significant treat-
ment or cure for RP [3-6].
RP is emotionally devastating to the patients due to
their anticipated vision loss, and the subsequent experi-
ence of gradual vision loss causes severe distress. These
factors could make RP patients more vulnerable to de-
pression, but few studies have addressed the issues of
depression and the vision-related quality of life in this
population [6].
Three clinical trials are being conducted in Brazil by
our research group on the use of autologous, bone
marrow-derived, hematopoietic stem cell transplantation
(auto-BMHSCT) for the treatment of RP, dry age-related
macular degeneration and ischaemic retinopathy (in-
cluding diabetic retinopathy with macular ischaemia)
[7]. These studies are registered with ClinicalTrials.gov,
numbers NCT01068561, NCT01518127 and NCT01518842,l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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clinical trial using an intravitreal injection of BM-derived
hematopoietic stem cells (CD34 +) for retinal dystrophy
(including RP) [8]. The second phase of this study
(NCT01560715) has already begun [9].
In the present report, we assess the quality of life status
of patients with RP submitted to intravitreal use of BM-
derived stem cells (Retinacell- clinical trial – phase 2)
using the National Eye Institute Visual Function Ques-
tionnaire (NEI-VFQ).Methods
The study protocol adhered to the tenets of the Declaration
of Helsinki and was approved by the National Commission
on Ethics in Research (CONEP) connected to the National
Health Council (CNS) of Brazil and registered in clinical-
trial.gov: NCT01560715.
The study was conducted in a single center (Hospital
das Clinicas, Medical School Ribeirao Preto- Sao Paulo-
Brazil). All participants gave written informed consent.
Patients were evaluated at the Retina and Vitreous
Section of the Department of Ophthalmology, Oto-
rhinolaryngology and Head and Neck Surgery, School
of Medicine of Ribeirão Preto, between April 2012 and
July 2013.
Throughout the study, a single certified examiner per-
formed Early Treatment Diabetic Retinopathy Study
best-corrected visual acuity (BCVA) measurement before
any other study procedure. Ophthalmic evaluation was
performed by a single retinal specialist (A.M.), and
stereoscopic fundus photography, fluorescein and indo-
cyanine green (ICG) angiography, microperimetry and
optical coherence tomography (OCT) were performed
by a single certified ophthalmic technician.Patient eligibility
Patients were included if they had: 1) a diagnosis of her-
editary retinal dystrophy classified clinically as RP or
cone–rod dystrophy, and 2) Early Treatment Diabetic Ret-
inopathy Study BCVA of 20/200 (or worse) or visual field
less than 20 degrees, considered legally blind. Exclusion
criteria were: 1) previous ocular surgery other than cata-
ract extraction; 2) presence of cataract or other media
opacity that would prohibit high-quality ocular imaging or
that would affect electroretinography (ERG) or visual field
evaluation; 3) presence of other ophthalmic disease, such
as glaucoma or uveitis; 4) history of blood disorders, such
as leukemia; 5) known allergy to fluorescein or ICG angi-
ography; or 6) known coagulation abnormalities or
current use of anticoagulative medication other than as-
pirin. If both eyes were eligible for treatment, the eye with
worse visual acuity was included in the study.Preparation of autologous bone marrow–derived stem cells
Aspiration of autologous bone marrow cells was per-
formed under local anesthesia. Bone marrow (10 ml)
was harvested from the posterior iliac crest and mono-
nuclear cells were separated by Ficoll–Hypaque gradient
centrifugation and suspended in buffered saline containing
5% human albumin at a concentration of 1 × 107 cells/ml.
The final product demonstrated absence of microbial
contamination.
The final 0.1 ml of cell suspension used for the intravit-
real injection contained 0.92 × 104 to 2.91 × 104 (mean:
1.68 × 104) bone marrow–derived hematopoietic stem
cells (CD34+).Intravitreal injection technique
All patients received an intravitreal injection using top-
ical proparacaine drops under sterile conditions (eyelid
speculum and povidone–iodine). Autologous (freshly
isolated) bone marrow–derived mononuclear cells were
injected into the vitreous cavity using a 27-gauge needle
inserted through the inferotemporal pars plana 3.0 mm
to 3.5 mm posterior to the limbus.
After the injection, central retinal artery perfusion was
confirmed by indirect ophthalmoscopy. Patients were
instructed to instill one drop of 0.3% ciprofloxacin into
the injected eye four times daily for one week after the
procedure.
The sham stem cell injection control procedure in-
volved anaesthetizing the contralateral eye in a manner
identical to that used for stem cell intravitreal injection.
The tip of a needleless syringe was then pressed against
the conjunctiva and the plunger of the needleless syringe
depressed.Visual functioning questionnaire
The NEI-VFQ was used to evaluate the patients’ subjective
visual function [10,11]. The NEI-VFQ-25 gives an overall
score, as well as 12 subscale scores: general health, general
vision, near vision, distance vision, driving, peripheral
vision, colour vision, ocular pain, vision-associated role
limitations, dependency, social functioning, and mental
health. The questionnaire focuses on vision difficulties
in everyday life, as well as vision-relevant psychosocial
domains, such as mental health, social function and role
difficulty. The patients filled out the package including
the questionnaire for demographic information and
NEI-VFQ, their responses were checked at the sched-
uled visit by a psychologist and if any were missing, the
patients were asked to fill them out.
The following data were collected: sex, age, education,
profession, and origin. All patients were instructed about
the objectives and methodology and gave written informed
consent to participate.
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that were transformed into percentages (0% to 100%).
Patients were scheduled to answer the questionnaire be-
fore treatment (baseline) and three and twelve months
after treatment.
After consultation with the Biostatistics Service, it was
decided to obtain the outcome by descriptive statistical
analysis. A P value of 0.05 was considered to be signifi-
cant in all analyses.
Results
All patients completed the survey as scheduled. We used
the Student’s t-test for statistical calculation.
There was a statistically significant improvement
(P <0.05) in the quality of life of patients three months
after treatment, whereas by the twelfth month there was
no statistically significant difference from baseline.
Figure 1 illustrates the behaviour of quality of life of
the patients based on the replies to the survey three to
twelve months after treatment, and Figure 2 shows a line
representing the average of all patients, more clearly re-
vealing the significant improvement by the third month
after treatment and the lack of a statistically significant
improvement by the twelfth month after treatment.
Discussion
In this article, we analyse the quality of life of patients
with RP submitted to cell therapy (Intravitreal Autolo-
gous Bone-Marrow Stem Cells) using the NEI-VFQ-25.
This study is part of a multiple investigation in which
we have previously evaluated the visual field, visual acu-
ity, fluorescein angiography, OCT and microperimetry in
these same patients [12].
In a previous part of this study, we also observed an
improvement in microperimetry in these 20 patients in
the third and twelfth month, possibly explaining the im-
provement in quality of life that we observed in theFigure 1 Quality of life behaviour of all patients submitted to cell thepresent analysis, which coincided with the findings of
microperimetry. However, in another study we did not
observe a decrease in retinal sensitivity in the twelfth
month as was observed in the present analysis of qual-
ity of life [13,14]. Therefore, we believe that there is
also a significant psychological component in these pa-
tients, because RP is a progressive degenerative disease
that leads to vision loss with no effective treatment and
the high expectations of these patients with respect to
this new kind of therapy may have influenced these
results.
The correlation between quality of life and the sensi-
tivity of the retina in patients with RP has been reported
in other studies [13,14].
Seo et al. [15] reported that functional visual score,
functional field score, and functional acuity score of the
American Medical Association guidelines were equally
correlated to those of the self-reported visual function
questionnaire (NEI VFQ-25) in RP patients. They sug-
gested that visual quality cannot be explained only by
visual acuity or visual fields in RP patients. Similarly,
macular sensitivity is also an important indicator of
quality of life in RP patients.
Sugawara et al. [16] demonstrated that vision-
related quality of life measured with the NEI VFQ-25
was significantly correlated with macular sensitivity
in RP patients whose visual acuity was relatively
good. These results indicate that macular sensitivity
determined by microperimetry (MP1) is a good pre-
dictor of quality of life in RP patients with relatively
good vision [16].
Park et al. [17] experimentally evaluated the behaviour
of bone marrow-derived stem cells when injected intra-
vitreally with respect to survival and clinical effect. They
determined that the intravitreally injected CD34 cells
were present in the retinal vasculature in the fourth
month after the injection and presented a clinical effectrapy.
Figure 2 Average quality of life behaviour of all patients submitted to cell therapy.
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month. These findings also concur with the clinical re-
sponse that we observed in our study and may explain
the fall in quality of life at the end of the first year. We
believe that, due to the temporary effect of this tech-
nique in these cases of retinal degeneration, a new dose
of intravitreal injection of stem cells is required for the
maintenance of a clinical effect.
Conclusions
The intravitreal use of bone marrow-derived stem cells
for the treatment of RP can improve the quality of life of
these patients at the third month visit but it deteriorates
afterwards.
This improvement may be related to improved micro-
perimetry and also to patient expectations. An analysis
after the second intravitreal injection of stem cells, taken
after the first year of treatment, may provide a better
definition of the influence of improvement in retinal
sensitivity (measured by microperimetry) and the psy-
chological component (patient expectations) on the re-
sults of the quality of life test.
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